Recent studies have indicated that FGFR4 deficiency might regulate the tumor immune microenvironment by activating the antigen presentation process and cellular immunity to the change in sensitivity to immune checkpoint inhibitor treatment in NSCLC [26]. This evidence concerns the gene FGFR4 and non-small cell lung carcinoma.